Merck Has Interesting News and Impressive Results

Merck Discontinues Development of COVID-19 Vaccine Candidates
Merck (MRK) known as MSD outside the United States and Canada announced yesterday that the company is discontinuing the development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591.

This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.